H.R. 8205

119th Congress

Introduced

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Sponsored byDemocrat:Rep. Quigley, Mike [D-IL-5]IL· Introduced 6 April 2026
Open on Congress.gov

103

Cosponsors

19

Actions

0

Amendments

1

Committees

—

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 0 of 0
Latest action

Motion to reconsider laid on the table Agreed to without objection.

22 July 2026·1 day ago

Summary

Reported to House · Updated 16 July 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The bill reauthorizes

  • grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
  • grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
  • a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. 

Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.

Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Timeline

19 actions

  1. Considered as unfinished business.

    22 July 2026 · Floor

  2. On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

    22 July 2026 · Floor

  3. Motion to reconsider laid on the table Agreed to without objection.

    22 July 2026 · Floor

  4. Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

    22 July 2026 · Floor

  5. DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.

    20 July 2026 · Floor

  6. Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

    20 July 2026 · Floor

  7. Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

    20 July 2026 · Floor

  8. Considered under suspension of the rules.

    20 July 2026 · Floor

  9. Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)

    20 July 2026 · Floor

  10. At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.

    20 July 2026 · Floor

  11. At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.

    20 July 2026 · Floor

  12. DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.

    20 July 2026 · Floor

  13. Placed on the Union Calendar, Calendar No. 637.

    9 July 2026 · Calendars

  14. Placed on the Union Calendar, Calendar No. 637.

    9 July 2026 · Calendars

  15. Placed on the Union Calendar, Calendar No. 637.

    9 July 2026 · Calendars

  16. Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

    9 July 2026 · Committee

  17. Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

    9 July 2026 · Committee

  18. Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

    9 July 2026 · Committee

  19. Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

    9 July 2026 · Committee

  20. Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

    9 July 2026 · Committee

Sponsorship

103 cosponsors

Sponsor

Democrat:Rep. Quigley, Mike [D-IL-5]IL

Cosponsors

  • Democrat3876%
  • Republican1224%
View all on Congress.gov

Classification

Policy area

Health

Committees

1

  • Energy and Commerce Committee

    House · Standing

    • Referred To6 Apr 2026
    • Markup By21 May 2026
    • Reported By9 Jul 2026

    • Health Subcommittee

      • Referred to6 Apr 2026
      • Markup by13 May 2026
      • Reported by13 May 2026

Reports

Pelosi Tracker
Follow on XJoin our Discord
PoliticiansBillsPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.